141 related articles for article (PubMed ID: 29749339)
41. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
42. Post-transplant lymphoproliferative disorder presenting as acute colonic perforation.
Dillon K; Sherigar J; Carey D; McManus DT; Lee J
Int J Colorectal Dis; 2007 Oct; 22(10):1287-8. PubMed ID: 16721488
[No Abstract] [Full Text] [Related]
43. Acute perforation of colonic diverticula associated with prolonged adrenocorticosteroid therapy.
Canter JW; Shorb PE
Am J Surg; 1971 Jan; 121(1):46-51. PubMed ID: 5540835
[No Abstract] [Full Text] [Related]
44. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
46. Colon perforation in an adolescent after short-term diclofenac intake.
Schiffmann L; Kahrau S; Berger G; Buhr HJ
ANZ J Surg; 2005 Aug; 75(8):726-7. PubMed ID: 16076342
[TBL] [Abstract][Full Text] [Related]
47. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
Quirino M; Rossi S; Schinzari G; Basso M; Strippoli A; Cassano A; Barone C
Medicine (Baltimore); 2017 Apr; 96(16):e6522. PubMed ID: 28422839
[TBL] [Abstract][Full Text] [Related]
48. Colonic perforation after nonsteroidal anti-inflammatory drug use in a 2.7-year-old boy.
Seon KA; Tseng SH; Weng CC; Chen Y
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):e41-3. PubMed ID: 25906455
[No Abstract] [Full Text] [Related]
49. Single dose regorafenib-induced hypertensive crisis.
Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
[TBL] [Abstract][Full Text] [Related]
50. Non-steroidal anti-inflammatory drugs and stercoral perforation of the colon.
Hollingworth J; Alexander-Williams J
Ann R Coll Surg Engl; 1991 Nov; 73(6):337-9; discussion 339-40. PubMed ID: 1759759
[TBL] [Abstract][Full Text] [Related]
51. Colonic perforation associated with slow-release diclofenac sodium.
Adhiyaman V; Asghar M; White AD
Int J Clin Pract; 2000 Jun; 54(5):338-9. PubMed ID: 10954963
[TBL] [Abstract][Full Text] [Related]
52. Thalidomide and bowel perforation: four cases in one hospital.
McClay H; Cervi P
Br J Haematol; 2008 Feb; 140(3):360-1. PubMed ID: 18042266
[No Abstract] [Full Text] [Related]
53. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
[TBL] [Abstract][Full Text] [Related]
54. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).
Bozzarelli S; Rimassa L; Giordano L; Sala S; Tronconi MC; Pressiani T; Smiroldo V; Prete MG; Spaggiari P; Personeni N; Santoro A
Future Oncol; 2019 Dec; 15(35):4009-4017. PubMed ID: 31746632
[No Abstract] [Full Text] [Related]
55. Treatment of colonic perforation after kidney transplantation.
Jeekel J; De Gruyl J; Mooy JM; Lameijer LD; Westbroek DL
Neth J Med; 1978; 21(3):117-9. PubMed ID: 351443
[No Abstract] [Full Text] [Related]
56. Intestinal perforation secondary to paclitaxel.
Rose PG; Piver MS
Gynecol Oncol; 1995 May; 57(2):270-2. PubMed ID: 7729749
[TBL] [Abstract][Full Text] [Related]
57. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
58. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
59. Collateral damage: taxane-induced colonic perforation.
Erdrich J; Kastenberg ZJ; DiMaio MA; Longacre TA; Rhoads KF
Dig Dis Sci; 2015 Feb; 60(2):313-5. PubMed ID: 25081225
[No Abstract] [Full Text] [Related]
60. Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.
Cicero G; De Luca R; Dieli F
Oncology; 2017; 93(6):354-358. PubMed ID: 28873372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
